Share |

End Mass Overdose Inc.

 1326 Columbia Road #4
 Boston, MA 02127
[P] (617) 645-8305
[F] --
http://www.endmassoverdose.org
[email protected]
Allison Burns
Facebook Twitter
INCORPORATED: 2015
 Printable Profile (Summary / Full)
EIN 47-3870286

LAST UPDATED: 04/17/2018
Organization DBA --
Former Names --
Organization received a competitive grant from the Boston Foundation in the past five years No

Summary

--

Mission StatementMORE »

Mission Statement: To provide innovative healthcare, education, and social services that engage, empower, and transform the community

Background: End Mass Overdose, Inc. is a 501c3 nonprofit organization that provides pharmacy-based strategies and solutions to improve access to care, optimize patient outcomes, and modernize the way we approach substance abuse and addiction in the United States.

Mission Statement

Mission Statement: To provide innovative healthcare, education, and social services that engage, empower, and transform the community

Background: End Mass Overdose, Inc. is a 501c3 nonprofit organization that provides pharmacy-based strategies and solutions to improve access to care, optimize patient outcomes, and modernize the way we approach substance abuse and addiction in the United States.


FinancialsMORE »

Fiscal Year July 01, 2017 to June 30, 2018
Projected Income $241,000.00
Projected Expense $245,892.00

ProgramsMORE »

  • Addiction Continuing Education and Workforce Development
  • Community Overdose Education and Naloxone (Narcan) Training
  • Opioid Education and Naloxone Training Course for Healthcare Workers and Other Professionals
  • Opioid Rescue
  • The Substance Use Disorder Pharmacy Program (SUDPP)

Revenue vs. Expense ($000s)

Expense Breakdown (%)

No data available

Expense Breakdown (%)

No data available

Expense Breakdown (%)

No data available

For more details regarding the organization's financial information, select the financial tab and review available comments.


Overview

Mission Statement

Mission Statement: To provide innovative healthcare, education, and social services that engage, empower, and transform the community

Background: End Mass Overdose, Inc. is a 501c3 nonprofit organization that provides pharmacy-based strategies and solutions to improve access to care, optimize patient outcomes, and modernize the way we approach substance abuse and addiction in the United States.


Background Statement

ADDRESSING THE OPIOID CRISIS AND ADDICTION THROUGH COMMUNITY ENGAGEMENT

End Mass Overdose's innovative partnerships and pharmacy-based services target gaps in care to foster community capacity development and integrative healthcare for addictive disorders and co-occurring mental illness. To balance the immediate and long-term needs of the community we have structured our services into 3 pillars that mirror the 3 stages of chemical dependency and overdose.

1. Prevention Services- Pre-Overdose: Utilize a knowledge-to-action cycle to identify gaps in knowledge, provide education, and then translate learning into practice

A. Continuing Education and Workplace Development Programs

B. Substance Abuse and Chemical Dependency Educational Guides and Training Manuals: Critical for professionals to provide adequate care and prevent unintentional opioid overdoses.

C. Advanced Pharmacy Practice Addiction Medicine Practicum and Clinical Training Program: first specialized training for Doctor of Pharmacy (PharmD) students in a residential treatment setting. Our program is a targeted response to address the unmet needs of the complex, dual-diagnosis patients.

2. Intervention Services- During Overdose: Focus on increasing access to naloxone and opioid overdose response training

A. Community Opioid Overdose Education and Narcan Training Sessions

B. Opioid Rescue SM first-of-its-kind traveling pharmacy and education program to increase access to Narcan (naloxone). Authorized by the MA Board of Pharmacy to turn any public space, including community centers, schools, gyms, and auditoriums, into a mobile pharmacy (pharmacy without walls) to legally dispense Narcan and provide drug education

3. Treatment Services- Post-Overdose: Address the challenges of treating substance abuse that inherently exist in a healthcare system siloed between medical, mental health, and social services

Substance Use Disorder Pharmacy Program (SUDPP): The SUDPP delivers coordinated care, reduces healthcare costs, and optimizes therapy outcomes to keep people in treatment. Includes:

  • Specialty prescription packaging to improve compliance and prevent diversion
  • Prescription delivery
  • Med reconciliation: develop the most accurate medication list
  • Medication Therapy Management (MTM): continuous quality assurance program and medication review to evaluate therapeutic appropriateness and safety
  • Compliance monitoring and non-adherence root cause analysis of behavior

Impact Statement

FY17 Milestones

  • Trained 1,000+ professionals in FY17, including Mass Housing Conference, Worcester County Elder Abuse Prevention/Central Mass Agency on Aging Conference, Cape Cod Outreach Continuing Pharmacy and Nursing Education Conference. Upcoming FY18 Spring programs (April 2018 to May 2018) include Women’s Recover Conference, DPH/BSAS Aging with Dignity Conference- Substance Abuse in Older Adults, Modern Assistance Programs Lecture Series on Alcohol and Drug Addiction, and the Massachusetts Nurses Association’s Understanding the Complexities of Impaired Practice in Health Professionals.
  • Commissioned to develop the content for educational materials, training guides, and manuals utilized by schools, organizations, professional associations, and employers, including the MA Department of Public Health, Massachusetts Pharmacists Association and Iowa National Guard Counterdrug Task Force
  • We established the first specialized clinical training for Doctor of Pharmacy (PharmD) students at Northeastern University and MCPHS University in a substance abuse residential treatment setting. Our program is a targeted response to address the unmet needs of the complex, dual-diagnosis patients suffering from a chemical dependency in Massachusetts. The program modernized the PharmD curriculum and expanded the role and competency level of new pharmacists entering practice.

Needs Statement

  1. Funding: financial support to fund our mission and services
  2. Social media and marketing assistance: experts to help us reach our target audience and disseminate information about our services to the community 
  3. Grant assistance: professional to assist us help obtaining local, state, and federal grants, including information on which grants are available to us and how to apply for them
  4. Business consultants: systems development to improve performance and optimize operational output 
  5. Volunteers: social advocates to help us engage the community and teammates to assist management 
 

CEO Statement

Often, I’ve found that “the problem” isn’t the problem. What do I mean? The identified problem is not a complete, all- inclusive problem. There are layers. So, what’s our problem? Americans are dying of opioid overdoses across the country.

Fact, opioid prescription sales and overdose deaths have increased concurrently over the past decade. The United States consumes 80 percent of the world’s opioids, but we represent 5 percent of the world’s population. Statistics show us that too many Americans are obtaining and using opioids, whether for legitimate medical use or illicitly from family and friends. The FDA, CDC, and many state legislatures have taken steps to better regulate the prescribing and dispensing of opioid prescriptions. Those in opposition to stricter regulations argue that limited access to opioids runs a greater risk of harming patients with chronic pain and does not significantly reduce addiction. Regardless of your stance on this ongoing debate, we are viewing the problem from the how perspective. We must also look at the problem from the why perspective. Americans are dying of overdoses has been identified as a national problem. How? Opioids. Okay, and why? Why are Americans misusing and abusing opioids?

We have identified the risk factors for opioid overdose, but we also need to target risk factors for opioid misuse, specifically trauma and mental illness. Mental illness includes low self-esteem, depression, anxiety, bipolar, mood and personality disorders. Traumatic experiences range from neglect to abuse. People will self-medicate and use chemical coping to feel better as long as there is distress, despair, and hopelessness. –Dr. Allison Burns, PharmD, RPh


Board Chair Statement

As clinicians, we have never refused treatment to the lung cancer patient or a diabetic having a heart attack at the door. We never send these patients away, blaming them for smoking cancer sticks or eating one too many cheeseburgers. Yet, society continually turns away those with substance use disorder and co-occurring mental illness, making them feel like they do not deserve treatment because they caused their own problems. This misconception is dangerously inaccurate and has only exacerbated the current public health crisis. There has been a significant lack of accountability. As a community, we need to utilize better assessments and treatment modalities to improve patient outcomes.


Geographic Area Served

City of Boston- Citywide (Indiv. neighborhoods also listed)
STATEWIDE
NATIONAL
GREATER BOSTON REGION, MA
We serve partners across the United States.  Our primary focus is the Greater Boston area.  

Organization Categories

  1. Public & Societal Benefit - Public & Societal Benefit NEC
  2. Mental Health & Crisis Intervention - Addictive Disorders NEC
  3. Education - Adult Education

Independent research has been conducted on this organization's theory of change or on the effectiveness of this organization's program(s)

Under Development

Programs

Addiction Continuing Education and Workforce Development

End Mass Overdose prevention (pre-overdose) services utilize a knowledge-to-action cycle to identify gaps in knowledge, provide education, and then translate learning into practice. Substance abuse and chemical dependency training is critical for professionals, educators, clinicians, and other workers to do the following:

  • Prevent unintentional opioid overdoses
  • Reduce stigma in the workplace
  • Improve public safety
  • Increase community awareness regarding substance abuse and addiction, including resources and options for care
  • Improve patient care
  • Reduce productivity costs in the workplace
  • Reduce healthcare costs
Budget  --
Category  Education, General/Other Education, General/Other
Population Served Adults Other Health/Disability People/Families of People with Health Conditions
Program Short-Term Success 
  • Improve workplace safety
  • Reduce stigma
  • Increase awareness regarding the national opioid epidemic and drug abuse
  • Provide professionals, educators, clinicians, and other workers with the tools to identify and respond to an overdose
Program Long-Term Success 
  • Standardize workplace policies and procedures to respond to employee substance abuse in an effective manner
  • Train crisis response teams to respond to substance abuse and overdose-related situations at public venues, especially those in the entertainment, athletic, transportation, and hospitality sectors
Program Success Monitored By 

Internal audit team

Examples of Program Success  Trained 1,000+ professionals in FY17, including Mass Housing Conference, Worcester County Elder Abuse Prevention/Central Mass Agency on Aging Conference, Cape Cod Outreach Continuing Pharmacy and Nursing Education Conference. Upcoming FY18 Spring programs (April 2018 to May 2018) include Women’s Recover Conference, DPH/BSAS Aging with Dignity Conference- Substance Abuse in Older Adults, Modern Assistance Programs Lecture Series on Alcohol and Drug Addiction, and the Massachusetts Nurses Association’s Understanding the Complexities of Impaired Practice in Health Professionals.

Community Overdose Education and Naloxone (Narcan) Training

Learn about opioid overdose and response:

  • Understand what opioids are, including lesser known opioids like tramadol and codeine, how these substances work, and how they cause an overdose
  • Risk factors for overdose
  • Identify difference between opioid intoxication (being "very high"), overdose, and withdrawal
  • Compare and contrast different formulations of naloxone (Narcan), including both intranasal products
  • Learn how to assemble and administer naloxone (Narcan)
  • Troubleshooting during an overdose, including broken Narcan device
  • Understand the roles of the community member and substance user in the opioid epidemic ​
Budget  $30,000.00
Category  Mental Health, Substance Abuse Programs, General/other Substance Abuse Crisis Intervention
Population Served Alcohol, Drug, Substance Abusers General/Unspecified Families
Program Short-Term Success  Short-term success will be increased number of community members trained in overdose prevention/response, increased access to naloxone, increase in number of standing orders, and increased community awareness.
Program Long-Term Success  Longterm success will be a reduction in the number of fatal overdoses. More specifically, a reduction in overdoses that correlates with increased access to naloxone per zip code.
Program Success Monitored By 

Immediate program success is monitored through an evaluation process which is utilized for all activities to assess whether, as a result of the participant attending the activity, there is a change in learner knowledge, competence, or skills from baseline. Either a paper or electronic evaluation will be utilized.

Longterm success is measured through an evaluation of overdose statistics and public health data provided by the Department of Public Health, CDC, and other governing bodies. Previous evidence has shown that overdose rates decrease in communities with access to overdose training and naloxone (Narcan).

Examples of Program Success  Examples of program success include a reduction in number of overdoses, decrease in number of hospital admittances for overdose-related events, and increase in number of naloxone rescue kits distributed.

Opioid Education and Naloxone Training Course for Healthcare Workers and Other Professionals

Instructional and training program that teaches healthcare workers, police officers, firefighters, social workers, teachers, coaches, counselors, and other professionals working with at-risk populations about overdose prevention and opioid therapy risk management. Program includes naloxone (intranasal and intramuscular) administrator training, opioid overdose recognition and response, including initial assessment of the victim and special precautions, overview of treatment agreements, Prescription Drug Monitoring (PMP) review, legal and liability considerations, and resources for treatment/recovery. Course includes Certificate of Completion
Budget  $20,000.00
Category  Mental Health, Substance Abuse Programs, General/other Substance Abuse Crisis Intervention
Population Served College Aged (18-26 years) Adults General/Unspecified
Program Short-Term Success  Short-term success will be effective delivery of training to Doctor of Pharmacy students in the 2016 spring semester at Massachusetts College of Pharmacy and Health Sciences (MCPHS). Inclusion of the program as a graduation requirement for students in all healthcare-related fields within MCPHS and eventual expansion of program to other campuses, colleges, universities, and training sites.
Program Long-Term Success  Long-term success will be establishing overdose education and opioid therapy risk management as a requirement for both graduation and renewal of licensure in all healthcare fields.
Program Success Monitored By  Program success will be monitored by student, preceptor, and patient surveys and testimonials. Survey questions will include, but are not limited to, is this training worthwhile for your career, how will this training improve patient care, what was the best and worst parts of training, and how can this training be improved. Student surveys will be administered after the initial training and again after assigned clinical rotations to determine if student used knowledge in practice. Preceptor surveys and patient testimonials will be used to determine if student was knowledgable and communicated this knowledge effectively.
Examples of Program Success  Program success will be measured by its sustainability, i.e. the inclusion and expansion of the program to other schools, hospitals, and training sites. Success will ultimately translate to better patient care.

Opioid Rescue

Opioid Rescue SM is first-of-its-kind traveling pharmacy and education program designed to increase access to the opioid overdose antidote naloxone (Narcan) and remove barriers to care in the community. Opioid Rescue is authorized by the Massachusetts Board of Pharmacy to turn any public space, including community centers, schools, gyms, churches, and auditoriums, into a mobile pharmacy (pharmacy without walls), where pharmacists can legally dispense naloxone rescue kits and provide drug education

Budget  $10,000.00
Category  Public, Society Benefit, General/Other Public, Society Benefit, General/Other
Population Served Alcohol, Drug, Substance Abusers Adults People/Families of People with Health Conditions
Program Short-Term Success 

Reduce stigma and remove barriers to care by bringing the prescription medication naloxone (Narcan) out of the pharmacy and into the community. Short-term goal: increase the number of people with access to naloxone

Program Long-Term Success 

Evidence-based results: national data has shown that areas with increased access to naloxone (Narcan) and overdose prevention training have lower rates of overdose fatality. Long-term goal: reduce the rate of unintentional overdose deaths

Program Success Monitored By 
Massachusetts Department of Health
Massachusetts Board of Pharmacy
Examples of Program Success  Data is currently being collected and analyzed to measure community impact through a State Targeted grant for Opioid Abuse

The Substance Use Disorder Pharmacy Program (SUDPP)

The Substance Use Disorder Pharmacy Program (SUDPP) is an innovative model of medication therapy management that brings pharmacy services and medical treatment under one roof. The SUDPP delivers coordinated care, reduces healthcare costs, and optimizes therapy to keep individuals in treatment. The following services are offered:

  • Medication dispensed in specialty packaging to improve compliance and prevent diversion
  • Prescription delivery directly to the residential facility. Allows patients to focus on recovery rather than spending hours at the pharmacy waiting for prescriptions to be filled
  • Drug protocol, policy and procedure development and systems analysis
  • Medication reconciliation: develop the most accurate medication list. Check each drug for correct dose, route, frequency, and directions at every transition in care to ensure that unnecessary medications are eliminated, and all medical conditions are being appropriately treated.
  • Medication Therapy Management (MTM): continuous quality assurance program with medication review and evaluation to assess therapeutic appropriateness and safety. The pharmacist will check each medication for therapy duplication, drug-drug/ drug- disease / drug-food interactions, allergies, potential for misuse and abuse, side effects, convenience, adherence, time to onset
  • Identification of medication-related issues: prioritize problem list, develop patient-specific action plan, intervene, and resolve
  • Compliance monitoring and non-adherence root cause analysis of behavior
Budget  --
Category  Mental Health, Substance Abuse Programs, General/other Substance Abuse
Population Served Alcohol, Drug, Substance Abusers Unemployed, Underemployed, Dislocated Poor,Economically Disadvantaged,Indigent
Program Short-Term Success 

Currently, serving Massachusetts Bureau of Substance Addiction Services (BSAS)-licensed substance use disorder programs, with focus on residential rehabilitation programs.

Current number of beds served: 169

Potential number of beds: 2,236

As of September 1, 2016, the total number of operational BSAS-licensed beds increased to 2,405 beds. Please note: one bed is not equivalent to one person. One bed serves multiple community members. There were 600 discharges among 2,398 beds in a one-month period (2014 MA Dept. of Public Health). Therefore, we serve many more than 169 people per month.

Program Long-Term Success  Long term goal is to serve all 2,236 beds in BSAS-licensed residential facilities in Massachusetts. Our goal is to improve the level of care and standardize care across the Commonwealth.
Program Success Monitored By  Massachusetts Department of Public Health - Bureau of Substance Addiction Services (BSAS)
Examples of Program Success 
  • Improvement in medication adherence
  • Decreased misuse and/or abuse of medications
  • Decreased diversion of prescription medications
  • Increased coordination of care
  • Decreased medication burden (number of prescriptions) per patient
  • Enhanced compliance to Hepatitis C treatment
  • Enhanced adherence to Medication-Assisted Treatment
  • Improved access to medications
  • Improved continuity of care

CEO/Executive Director/Board Comments

The opportunities to provide prescription drug and overdose prevention, training, and treatment services are greatly needed during the current opioid epidemic.  The greatest challenge is bringing our comprehensive services and programs to as many communities as possible in the shortest amount of time in order to provide effective public health crisis intervention. 

Management


CEO/Executive Director Dr. Allison Burns
CEO Term Start May 2015
CEO Email [email protected]
CEO Experience

SUMMARY OF QUALIFICATIONS

  • Founder and Chief Executive Officer of End Mass Overdose, Inc. and Atlas Health Partners Corporation
  • Innovator of pharmacy-based solutions; invented Opioid RescueSM (patent pending), the Substance Use Disorder Pharmacy Program, and the Addiction Medicine Practicum/Clinical Training Program
  • Academic faculty and clinical instructor at MCPHS University and Northeastern University
  • 9 years of professional leadership and military experience
  • 6 years of diverse clinical experience—community, residential, ambulatory, pain, addiction, long term care
  • 3 years of patient advocacy as member of state and local advisory boards and committees

EDUCATION

  • Doctor of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, 2016
  • Bachelor of Science, United States Naval Academy, 2009

PROFESSIONAL EXPERIENCE

  • The Exit Team, Cohost, January 2018 to Present
  • Atlas Health Partners Corporation, Chief Executive Officer, January 2018 to Present
  • Massachusetts Department of Public Health, Pharmacist Consultant and Advisor for Bureau of Substance Addiction Services, July 2017 to Present
  • End Mass Overdose, Inc., President and Chief Executive Officer, May 2015 to Present
  • United States Naval Reserves, Intelligence Officer, December 2010 and May 2017
  • Beth Israel Deaconess Medical Center, Resident PGY1 Pharmacy Practice, June 2016 to January 2017
  • CVS Pharmacy, January 2011 to December 2015
  • United States Navy, Commissioned Officer-Aviation, May 2009 to December 2010

PROFESSIONAL AFFILIATIONS AND COMMITTEES

MA Dept. of Public Health Pharmacy Workgroup; Boston Women's Leadership Council; Recovery Matters Committee Member; Massachusetts Pharmacists Association: Operation Prevention Advisory Committee; Maximizing Opioid Safety with Naloxone (MOON) Study Advisory Board Member

LICENCES & CERTIFICATIONS

Registered Pharmacist License: PH236757; Recovery Coach Trainer; Narcan Trainer of Trainers, Phlebotomy/IV Certificate, Medication Therapy Management Certificate

Co-CEO --
Co-CEO Term Start --
Co-CEO Email --
Co-CEO Experience --

Former CEOs and Terms

Name Start End
-- -- --

Senior Staff

Name Title Experience/Biography
-- -- --

Awards

Award Awarding Organization Year
Innovation in Pharmacy Award Usher-Smith Laboratories 2017
11th Annual Advanced Practice Management Business Competition- First Place Massachusetts College of Pharmacy and Health Sciences 2015

Affiliations

Affiliation Year
-- --
Member of state association of nonprofits? No
Name of state association --

External Assessments and Accreditations

External Assessment or Accreditation Year
-- --

Collaborations

End Mass Overdose, Inc. has collaborated with several organizations, schools, medical centers, and community groups on a state and national level:
  • Massachusetts Department of Public Health 
  • Massachusetts Board of Pharmacy 
  • Boston Medical Center
  • Hope House Addiction Services
  • Iowa Counterdrug Task Force
  • Safe Project US
  • Boston Neighborhood Network (BNN)
  • South Shore FACTS 
  • Massachusetts College of Pharmacy 
  • Northeastern University 
  • Brandeis University 
  • Massachusetts Nurses Association 
  • Massachusetts Pharmacists Association 
  • Massachusetts Council on Aging
  • Amazon Charity Foundation 
  • Massachusetts Health Council 
  • Middlesex Human Services Agency 

CEO/Executive Director/Board Comments

--

Foundation Comments

--

Staff Information

Number of Full Time Staff 1
Number of Part Time Staff 4
Number of Volunteers 10
Number of Contract Staff 0
Staff Retention Rate % 100%

Staff Demographics

Ethnicity African American/Black: 1
Asian American/Pacific Islander: 3
Caucasian: 9
Hispanic/Latino: 1
Native American/American Indian: 0
Other: 2
Other (if specified): Middle Eastern
Gender Female: 9
Male: 6
Not Specified 0

Plans & Policies

Organization has Fundraising Plan? Under Development
Organization has Strategic Plan? Under Development
Years Strategic Plan Considers 1
Management Succession Plan Under Development
Business Continuity of Operations Plan No
Organization Policies And Procedures Under Development
Nondiscrimination Policy Yes
Whistle Blower Policy Yes
Document Destruction Policy Yes
Directors and Officers Insurance Policy Yes
State Charitable Solicitations Permit Yes
State Registration Yes

Risk Management Provisions

--

Reporting and Evaluations

Management Reports to Board? N/A
CEO Formal Evaluation and Frequency Yes Annually
Senior Management Formal Evaluation and Frequency Yes Annually
Non Management Formal Evaluation and Frequency Yes Annually

Governance


Board Chair Dr. Allison Burns
Board Chair Company Affiliation President
Board Chair Term May 2016 - May 2018
Board Co-Chair Sgt Brendan Douglas
Board Co-Chair Company Affiliation Clerk
Board Co-Chair Term May 2016 - May 2018

Board Members

Name Company Affiliations Status
Dr. Allison Burns President, CEO Voting
Sergeant Brendan Douglas Director of Law Enforcement Engagement, Clerk Voting
Dr. Cameron Dumas Director of Finance, Treasurer Voting
Dr. Joseph Ferullo Director of Business Development Voting

Constituent Board Members

Name Company Affiliations Status
-- -- --

Youth Board Members

Name Company Affiliations Status
-- -- --

Advisory Board Members

Name Company Affiliations Status
-- -- --

Board Demographics

Ethnicity African American/Black: 0
Asian American/Pacific Islander: 1
Caucasian: 5
Hispanic/Latino: 0
Native American/American Indian: 0
Other: 1
Other (if specified): Middle Eastern
Gender Female: 2
Male: 5
Not Specified 0

Board Information

Board Term Lengths 2
Board Term Limits 0
Board Meeting Attendance % 100%
Written Board Selection Criteria Yes
Written Conflict Of Interest Policy Yes
Percentage of Monetary Contributions 25%
Percentage of In-Kind Contributions 100%
Constituency Includes Client Representation No

Standing Committees

  • --

CEO/Executive Director/Board Comments

--

Foundation Comments

--

Financials


Revenue vs. Expense ($000s)

Expense Breakdown (%)

No data available

Expense Breakdown (%)

No data available

Expense Breakdown (%)

No data available

Fiscal Year July 01, 2017 to June 30, 2018
Projected Income $241,000.00
Projected Expense $245,892.00
Form 990s

2017 990-N

2016 990-N

2015 990-N

Audit Documents

2019 Operational Budget FY18 and FY19

IRS Letter of Exemption

IRS Letter of Determination

Prior Three Years Total Revenue and Expense Totals

Fiscal Year -- -- --
Total Revenue -- -- --
Total Expenses -- -- --

Prior Three Years Revenue Sources

Fiscal Year -- -- --
Foundation and
Corporation Contributions
-- -- --
Government Contributions -- -- --
    Federal -- -- --
    State -- -- --
    Local -- -- --
    Unspecified -- -- --
Individual Contributions -- -- --
Indirect Public Support -- -- --
Earned Revenue -- -- --
Investment Income, Net of Losses -- -- --
Membership Dues -- -- --
Special Events -- -- --
Revenue In-Kind -- -- --
Other -- -- --

Prior Three Years Expense Allocations

Fiscal Year -- -- --
Program Expense -- -- --
Administration Expense -- -- --
Fundraising Expense -- -- --
Payments to Affiliates -- -- --
Total Revenue/Total Expenses -- -- --
Program Expense/Total Expenses -- -- --
Fundraising Expense/Contributed Revenue -- -- --

Prior Three Years Assets and Liabilities

Fiscal Year -- -- --
Total Assets -- -- --
Current Assets -- -- --
Long-Term Liabilities -- -- --
Current Liabilities -- -- --
Total Net Assets -- -- --

Prior Three Years Top Three Funding Sources

Fiscal Year -- -- --
1st (Source and Amount) -- --
-- --
-- --
2nd (Source and Amount) -- --
-- --
-- --
3rd (Source and Amount) -- --
-- --
-- --

Financial Planning

Endowment Value --
Spending Policy Income Only
Percentage(If selected) --
Credit Line Yes
Reserve Fund No
How many months does reserve cover? --

Capital Campaign

Are you currently in a Capital Campaign? Yes
Capital Campaign Purpose To raise funding to expand our Substance Use Disorder Pharmacy Program to more residential treatment facilities serving the high-risk addiction and co-occuring mental illness.
Campaign Goal $30,000.00
Capital Campaign Dates Apr 2018 - June 2019
Capital Campaign Raised-to-Date Amount --
Capital Campaign Anticipated in Next 5 Years? Yes

Short Term Solvency

Fiscal Year -- -- --
Current Ratio: Current Assets/Current Liabilities -- -- --

Long Term Solvency

Fiscal Year -- -- --
Long-term Liabilities/Total Assets -- -- --

CEO/Executive Director/Board Comments

--

Foundation Comments

This organization is newer and received its nonprofit status from the IRS in July 2015, per the above posted IRS Letter of Determination. The organization files a 990-N/Postcard with the IRS.

Impact

The Impact tab is a section on the Giving Common added in October 2013; as such the majority of nonprofits have not yet had the chance to complete this voluntary section. The purpose of the Impact section is to ask five deceptively simple questions that require reflection and promote communication about what really matters – results. The goal is to encourage strategic thinking about how a nonprofit will achieve its goals. The following Impact questions are being completed by nonprofits slowly, thoughtfully and at the right time for their respective organizations to ensure the most accurate information possible.


1. What is your organization aiming to accomplish?

The goal of End Mass Overdose, Inc. (EMO) is to provide opioid epidemic response and strategy.  EMO recommends intervention strategies and implements programs to reduce barriers to naloxone access, maximize opioid safety awareness and education, and connect and strengthen existing systems, such as the Prescription Drug Monitoring Programs.  EMO will become the leader on substance abuse prevention, education, and treatment in the Commonwealth of Massachusetts. With success, we hope to serve as a framework for other overdose education and naloxone distribution programs throughout the country.  

2. What are your strategies for making this happen?

End Mass Overdose, Inc. provides opioid epidemic response and strategy through a variety of comprehensive services that reduce the number of overdoses and drug-related costs.  The short term harm reduction and overdose prevention strategy is to increase access to naloxone (opioid overdose reversal agent), provide opioid training and certification courses, and raise awareness/reduce the stigma of addiction through de-stigmatization campaign.  The long term strategy is to distribute naloxone at every overdose training sessions,  offer combined CPR and naloxone training certifications, and make opioid therapy risk management mandatory mandatory for both renewal of healthcare professional licensure and for graduation from a healthcare-related professional program.  
 
Currently, CEO and President Allison Burns sits on the Advisory Board for Maximizing Opioid Safety with Naloxone at Boston Medical Center and collaborates on an interstate level to advise stakeholders in state government, academia, and the community on overdose prevention and reduction strategies in Massachusetts and Rhode Island.  This interstate collaboration has been helpful in analyzing strategies that work and reform programs that do not and has served as a springboard for her to promote and implement successful strategies used End Mass Overdose, Inc.  

3. What are your organization’s capabilities for doing this?

End Mass Overdose, Inc. (EMO) is one of two state-approved opioid antagonist training programs by the Massachusetts Department of Public Health and the Board of Registration in Pharmacy.  EMO has partnered with several other community organizations and coalitions to increase access to our services.  Our DPH endorsement and referrals has allowed us to serve communities throughout the Commonwealth.  Our partnership with MCPHS University has allowed us to pioneer and launch an opioid therapy and harm reduction course, which is mandatory for all Doctor of Pharmacy students in the 2016 spring semester.  We hope to show the value of this training and make it a graduation requirement for all healthcare professionals in order to promote better prescribing practices and broader public health goals.  Our diverse Board of Directors has allowed us to reach a broad target audience and establish a presence in academia, police departments, pharmacies, and several hospitals, including the VA Boston Healthcare System, Brigham & Women's Hospital, Massachusetts General Hospital, and Kindred Hospital.  EMO's core internal strength is our staff's expertise and patient-centered skills (3 staff members hold Doctorate-level healthcare degrees).   Our core external strength is our partnerships and endorsements.  These combined strengths allow EMO to offer a variety of substance abuse services, advocacy, and crisis intervention to reach all those impacted by this public health crisis, from struggling addicts and concerned families to medical personnel, counselors, teachers, firemen, and police officers.  

4. How will your organization know if you are making progress?

Outcomes Assessment

An evaluation process is utilized for all activities to assess whether, as a result of the participant attending the activity, there is a change in learner knowledge, competence, or skills from baseline. Either a paper or electronic evaluation will be utilized. The link to the electronic survey and evaluation form is sent via email to the participants within 24-48 hours of activity completion. Attendance is tracked via mandatory sign in sheet, where participants are asked to list their email addresses. For participants who do not have computer access or prefer to not provide an email address, a paper survey and evaluation form is provided on-site at the activity to evaluate changes in learner knowledge, competence, and skills from baseline. Both the electronic and paper evaluations also include a section to provide feedback about the course/training event and the instructors.

Outcome Levels to be Achieved

· Level 1: participation

o Source of data: attendance records

· Level 2: satisfaction

o Source of data: questionnaire/survey completed by attendees after the educational activity

· Level 3: learning and procedural knowledge

o Source of data: pre and post-tests of knowledge, self-report of knowledge gained in post-activity survey

· Level 4: Competence

o Source of data: observation in educational setting; will observe attendees assemble naloxone rescue kits

 
 
Progress and success is measured by public health and overdose data provided by the DPH, CDC, and other governing bodies.  EMO also analyzes data from focus groups, pharmacies, and hospitals to evaluate the impact and effectiveness of our recommended initiatives. An example of our business metrics includes the following: a reduction in the number of overdoses is a sign of progress.  A reduction in fatal overdoses that correlates with increased naloxone access per zip code is a measure of success.  Increased use of the Prescription Drug Monitoring Program (PMP) is a measure of progress.  A reduction in the number of prescriptions written and dispensed for painkillers per pharmacy location is a measure of success.  Key milestones include establishing a Standing Order for Naloxone (SON) in every town in Massachusetts, increasing naloxone distribution, and establishing substance abuse training as a mandatory graduation and renewal requirement in pharmacy and other healthcare professions.  
 
EMO recognizes it must continuously redefine its market based on drug trends. Over the years, heroin use has evolved as users began to take it simultaneously with prescription drugs, namely Percocet, and as suppliers began to cut their product with the painkiller Fentanyl to increase profits and potency. EMO recognizes the significance of these social trends, both as a contributing factor to the lethality of drug use and as a driving force in our dynamic marketplace. To best serve our client base and achieve our mission of addiction harm reduction, EMO’s R&D Department pledges to stay current on emerging drug patterns per area. Existing programs have failed to update with current drug fads and thus, their services have become less effective over time.  EMO utilizes reports from its expert staff of pharmacists, police officers, and veterans, as well as anonymous feedback from community members, recovering addicts, and current users to stay up-to-date and adjust its services to best serve the public. 

5. What have and haven’t you accomplished so far?

Current accomplishments include connecting community members and groups with the resources needed to reduce overdose-related events, such as setting up Standing Orders for Naloxone (SON), hosting awareness events, and providing overdose education and naloxone certification for professionals, families, and substance users.  A potential obstacle is a lack of understanding and knowledge of the barriers to naloxone access.  One major barrier is although Massachusetts has passed legislation that allows for a standing order, that does not guarantee that every pharmacy has taken the steps to establish the order.  Setting up an order takes time, resources, knowledge, and supervisor approval. Consequently, many community pharmacies do not stock or dispense naloxone without a prescription.  End Mass Overdose, Inc. removes these burdens, sets up the standing order on behalf of the pharmacy, trains the staff on counseling and billing procedures, offers certification courses for bystanders, and publicizes that naloxone is available to the community.  Another barrier to naloxone access is the skyrocketing price of the drug.  EMO is working to establish a relationship with the pharmaceutical companies to purchase and provide discounted and/or free supply to the community.  Overall, EMO's greatest obstacle to providing any and all of our services is funding to sustain our operations.